secwatch.observer — SEC 8-K summary
======================================

Issuer:     Zentalis Pharmaceuticals, Inc. (ZNTL)
CIK:        0001725160
Form:       8-K
Filed at:   2023-02-13T23:59:59+00:00
Accession:  0001725160-23-000028
Event type: leadership
Sentiment:  positive
Materiality: 0.35
Item codes: 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Zentalis appoints Iris Roth as COO, effective Feb 13, 2023
----------------------------------------------------------

- Iris Roth, Ph.D. appointed Chief Operating Officer effective February 13, 2023.
- Dr. Roth previously led CD226 Axis immune checkpoint inhibitor development at GSK as VP Medicine Development Leader.
- Initial base salary $434,476; target bonus 40% of base; severance for involuntary termination.
- Granted stock options for 297,500 shares and RSUs for 52,500 shares, vesting four years.
- Severance includes 9 months salary (12 months after change in control) and COBRA coverage.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1725160/000172516023000028/0001725160-23-000028-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1725160/000172516023000028/zntl-20230213.htm
  HTML page:      https://secwatch.observer/filing/0001725160-23-000028

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer